Compare EPR Properties (EPR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Vertex Pharmaceuticals Incorporated — how do they compare? EPR Properties trades at $60 (market cap $4.63B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 28.7× EPR Properties's market cap, and EPR Properties pays a 6.16% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| EPR | VRTX | |
|---|---|---|
Market Cap | $4.63B | $132.79B |
Sector | Real Estate | Health |
52-Week High | $64.32 | $529.65 |
52-Week Low | $48.71 | $376.62 |
Enterprise Value | $8.14B | $126.92B |
Dividend Yield | 6.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $62.20, up 1.4% today, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong profitability with a 91.41% gross margin and raised 2026 FFO guidance, supported by a new $1.6 billion credit facility announced on July 20, 2026. Key resistance is at $63, with support at $61.
Outlook is cautiously positive given analyst consensus of $65.30 price target and dividend stability, but risks include declining net income margins and high valuation multiples. Investment appeal hinges on execution of acquisition strategy amid economic sensitivity.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
